Prognostic significance of histopathological subtypes in stage I pure yolk sac tumour of the ovary. by Sasaki, H. et al.
Br. J. Cancer (1994), 69, 529-536 1994
Prognostic significance of histopathological subtypes in stage I pure yolk
sac tumour of the ovary
H. Sasaki', M. Furusato2, S. Teshima3, T. Kiyokawal, A. Tadal, S. Aizawa2, T. Yamabe4,
S. Tsuganes & Y. Terashimal
'Department ofObstetrics and Gynecology and 2Department ofPathology, The Jikei University School ofMedicine, Tokyo,
Japan; 3Department ofPathology, Fraternity National Memorial Hospital, Tokyo, Japan; 4Department ofObstetrics and
Gynecology, Nagasaki University, Nagasaki, Japan; 5Epidemiology Division, National Cancer Center Research Institute, Tokyo,
Japan.
Summary The correlation between histological subtype [endodermal sinus (ES), polyvesicular vitelline (PV),
glandular (G) and hepatoid (H) subtypes] and the prognosis of pure yolk sac tumours (YSTs) of the ovary was
investigated. From 1964 to 1989, 35 patients with YSTs were treated with primary surgery and adjuvant
chemotherapy. The prevalence of histological subtypes was as follows: 14 patients had a single subtype, either
ES (12) or G (2); 12 patients had two subtypes, ES+G (4), ES + PV (3), ES + H (4) or G + H (1); six patients
had three subtypes, ES + PV + H (4) or ES + G + H (2); and three patients had all four subtypes. Multi-
variate analysis showed that important predictors were FIGO stage, chemotherapeutic regimen and residual
tumour size. However, for stage I, multivariate analysis showed that the histological subtype was a superior
predictor to the subclassification of FIGO stage I, age or chemotherapeutic regimen (P = 0.03). Kaplan-Meier
analysis showed that YSTs composed of an admixture of three or four subtypes was associated with a better
prognosis than those composed of one or two subtypes (P<0.01), other variables being constant.
Ovarian yolk sac tumour is a relatively uncommon ovarian
neoplasm; however, it is one of the most common malignant
ovarian neoplasms of childhood, adolescence and early adult
life (Huntington et al., 1963). Yolk sac tumours exhibit a
wide range of histological subtypes that differ considerably
from each other and, although all the different subtypes are
frequently observed in the same tumour, one or two may
predominate (Teilum, 1965, 1968, 1976; Duval, 1891; Jimer-
son & Woodruff, 1977). The majority of ovarian yolk sac
tumours show a distinctive subtype with differentiation
towards yolk sac or vitelline structures (Teilum, 1959; Kur-
man & Norris, 1976; Huntingdon & Bullock, 1970), and
should be termed yolk sac tumour. During embryogenesis,
the primary yolk sac differentiates during the second week of
gestation, the secondary yolk sac in the third week and the
primitive gut and liver tissues in the fourth to fifth weeks of
gestation. In comparing the embryonic structures with the
neoplastic subtypes, these various embryonic stages corres-
pond to the endodermal sinus, polyvesicular vitelline, glandu-
lar and hepatoid subtypes respectively. Therefore, yolk sac
tumours with glandular or hepatoid subtypes reflect more
advanced stages of differentiation than those with pure endo-
dermal sinus subtypes.
Kurman and Norris (1976) dividied the components of
endodermal sinus tumour into five main histological sub-
types, but they were unable to determine any correlation of
these with prognosis. YST of the ovary is a highly malignant
neoplasm, metastasising early and invading the surrounding
structures and organs. The tumour is very aggressive locally,
and spread beyond the ovary is observed in a number of
patients at the time of operation. Recurrences in the pelvis
are very frequent, even when the tumour and the affected
adnexa have been excised completely (Huntington et al.,
1963; Kurman & Norris, 1976; Huntington, 1970; Neubeccker
& Breen, 1962; Talerman et al., 1978). In recent years there
has been marked improvement in prognosis with adjuvant
multiagent combination chemotherapy. Previously, a com-
bination of vincristine, dactinomycin and cyclophosphamide
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(VAC) was the standard regimen for the treatment of germ
cell tumours (Gershenson et al., 1985). However, a combina-
tion of cisplatin, etoposide and bleomycin (BEP) (Smales &
Peckman, 1987; Pinkerton et al., 1986; Gershenson et al.,
1990; Williams et al., 1989) or cisplatin, vinblastine and
bleomycin (PVB) (Bradof et al., 1982; Taylor et al., 1985;
Einhorn & Donohue, 1977; Julian et al., 1980; Carlson et al.,
1983; Davis et al., 1984) has been found to be even more
effective and has produced remissions in patients with
advanced-stage disease and in patients in whom other com-
binations of multiagent chemotherapy have failed (Bradof et
al., 1982; Taylor et al., 1985; Einhorn & Donohue, 1977;
Julian et al., 1980; Carlson et al., 1983; Davis et al., 1984;
Smales & Peckman, 1987; Pinkerton et al., 1986; Williams et
al., 1989; Gershenson et al., 1990). Cisplatin-based combina-
tion chemotherapy has revolutionised the treatment of
patients with yolk sac tumour.
We thought that differences in histological subtypes might
have prognostic significance. Recently it was reported that
the intestinal subtype (primitive endodermal) is histologically
more differentiated, and this subtype is found more often in
stage I patients (Kawai et al., 1991). In the same study, the
intestinal and microcystic subtypes were more common in
survivors than in non-survivors, but the number of patients
was considered to be too small for analysis (Kawai et al.,
1991). More extensive studies are needed to determine whether
intestinal and hepatoid subtypes are biologically different from
other types of YST.
In this report, clinicopathological evaluation was performed
in 35 patients with pure YST of the ovary, particularly those
with stage I disease, to determine if there is a correlation
between prognosis and the various histological subtypes.
Patients and methods
The study group consisted of 35 patients (Table I) with pure
yolk sac tumours of the ovary. The 35 patients were from 16
centres: the Departments of Obstetrics and Gynaecology of
Nagasaki University (2), Kurume University (4), National
Kyushu Cancer Centre (CTR) (3), Nagoya University (3),
National CTR (5), Kitazato University (2), The Jikei Univer-
sity (1), Tohoku University (1), National Sendai Hospital (3)
Niigata University (2) and Sapporo Medical University (9). All
patients had primary surgery performed prior to chemotherapy
or irradiation from 1963 to 1989. The 35 patients were all
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Table I Prevlance of histological subtypes in ovarian pure yolk sac tumours
Number ofpatients
Number ofhisto- Histological with each subtype Number ofhistopathological slides
pathological subtypes subtype (%) (mean+s.d.)
One ES 11 (31.4)
PV 0 (0) 5.57±5.05
G 2 (5.7)
H 0 (0) P=0.5
13 (37.1) P= 0.09
Two ES + PV 3 (8.6)
ES+G 4(11.4)
ES+H 5 (14.3) 6.90±3.60 P= 0.02
G+H 1 (2.9)
G+PV 0 (0) P=0.7
H+PV 0(0)
13 (37.1) P = 0.1
Three ES + PV + H 4 (11.4) 1
ES+G+H 2 (5.7) 15.00 12.52
ES+PV+G 0(0)
PV+G+H 0 (0) P = 0.6
6 (17.1)
Four ES +PV+G+ H 3 (8.6) 11.33 5.03
3 (8.6)
Total 35 (100) 8.03±7.14
Abbreviations: ES, endodermal sinus subtype; PV, polyvesicular vitelline subtype; G, glandular subtype; H,
hepatoid subtype. All statistical calculations were performed by Fisher's t-test.
Percentage ofpatients in all cases Percentage ofpatients in stage I
Histological subtypes (n = 35) (n = 17)
ES 32/35 (91.4%) 15/17 (88.2%)
PV 10/35 (28.6%) 8/17 (47.1%)
G 11/35 (31.4%) 8/17 (47.1%)
H 14/35 (40.0%) 8/17 (47.1%)
Japanese women between 1 and 48 years of age. All histo-
pathological diagnoses were reviewed by a single pathologist
(S. Teshima) and a single gynaecological oncologist (H.
Sasaki). A total of 1-40 tissue sections (mean ± s.d. 8.03 ±
7.14) were studied in each case. Routine haematoxylin and
eosin staining was supplemented by periodic acid-Schiff (PAS)
with and without predigestion with diastase and mucicarmine
staining. The major histological subtypes of all patients were
classified microscopically according to a modified classification
of Teilum's (Teilum, 1959, 1976), Kurman's (Kurman &
Norris, 1976) and Ulbright's methods (Ulbright et al., 1986),
which was composed of ES, PV, G and H subtypes. The ES
subtype is consistent with Kurman's reticular subtype contain-
ing Schillar-Duval bodies (Figure 1) (Kurman & Norris,
1976). The PV subtype corresponds to Kurman's polyvesicular
vitelline subtype (Figure 2) (Kurman & Norris, 1976). The G
subtype is equal to Ulbright's enteric differentiation (Figure 3)
(Ulbright et al., 1986). The H subtype is equal to Ulbright's
hepatic differentiation (Figure 3) (Ulbright et al., 1986). All
patients were classified according to FIGO staging (Interna-
tional Federation ofGynecology and Obstetrics, 1988). Perfor-
mance status (PS) was classified according to Karnofsky
criteria. Alpha-fetoprotein values were measured in 27
patients. All patients underwent primary surgery consisting of
unilateral salpingo-oophorectomy (SO), bilateral salpingo-
oophorectomy (BSO), BSO + total hysterectomy (TAH) and
SO, BSO, or BSO + TAH with para-aortic or pelvic lymph-
adenectomy (LNX). Omentectomy (OMTX) or creation of a
bowel stoma was performed in addition to the above surgical
procedures in some cases. Diagnostic laparatomy was per-
formed in only one case. Thirty-three patients (94.3%) received
adjuvant chemotherapy including VAC (vincristine, dactino-
mycin and cyclophosphamide), PVB (cisplatin, vinblastine and
bleomycin), PAC (cisplatin, adriamycin and cyclophospha-
mide), FAM (5-fluorouracil, cyclophosphamide and mito-
mycin), FAMT (FAM and toyomycin) and other regimens.
The administered dosages were as follows. PVB: cisplatin
(CDDP) 35 mg m-2 i.v. on day 1, vinblastine (VB) 7 mgm-2
i.v. on day 1 and bleomycin (B) 10 mgm-2 on days 1, 3 and 5;
PAC: CDDP 35 mg m-2 i.v. on day 1, adriamycin (A) 35 mg
m_2 i.v. on day 1, cyclophosphamide (CPM) 200 mgm-2 i.v.
on day 1; PEP: CDDP 50 mgm-2, pepleomycin 7mg m-,
etoposide 100 mgm-2 i.v. on day 1, PAF: CDDP 70 mgm2,
CPM 300 mgm-2 i.v. on day 1, 5-fluorouracil (5-FU)
200mg m-2 i.v. on days 1 to 5; VAC: vincristine (VC)
1 mgm-2 i.v. on day 1, dactinomycin (ActD) 0.5 mgm-2 i.v.
on days 1 to 5, CPM 200 mgm2 i.v. on days 1 to 5; FAM:
5-FU 200 mg m-2 i.v. on days 1 to 5, CPM 300mgm-2 i.v. on
day 1; FAMT: FAM + toyomycin 0.35 mgm-2 i.v. on day 1;
others: CPM 50 mgm-2 + MMC 5 mgm-2 i.v. on day 1,
MMC 4mgm-2 i.v. on day 1, ActD 0.5mgmM2 +carbo-
quinone 5mgm-2 i.v. on day 1, B 20mgm 2 i.v. on day 1
and methotrexate 14mgm-2 i.v. on day 1.
Sixteen patients were subsequently treated with chemo-
therapeutic agents different from the initial ones. Whole-
abdomen or whole-pelvic radiation was given in four cases
after adjuvant chemotherapy or at recurrence. Follow-up
information was obtained for all 35 patients. The follow-up
period ranged from 2 days to 3,304 days (median 860.5 days).
Statistical analysis
The survival rates were calculated using the Kaplan-Meier
method (Kaplan & Meier, 1972). Differences in survival
among various groups were assessed with the log-rank test.
In order to further analyse prognostic factors, we adopted
the proportional hazard regression model of Cox (1972). All
of the variables were used to develop a multiple regression
model. The model was elaborated in keeping with the partial
likelihood theory and estimated the regression coefficients
expressing the relation between covariates and survival. Sur-
vival time was calculated by considering deaths from all cases
and was calculated for treated patients only. The sets of
variables analysed for all cases in the Cox model were as
follows: FIGO stage I = 1, II = 2, III = 3, IV = 4; number of
histological subtypes, one = 3, two = 2, three or four = 1;PURE YOLK SAC TUMOUR OF THE OVARY 531
Figure 1 Endodermal sinus subtype, composed of fine papillary Figure 3 Glandular subtype composed of cystic glands of vary-
and perivascular structures formed by a layer of low columnar or ing size surrounded by oedematous stroma. The cells are colum-
cuboidal epithelial-like cells. Many hyaline bodies are also seen nar or cuboidal epithelial-like, and contain abundant clear cyto-
( x 100). plasm ( x 100).
Figure 2 Polyvesicular vitelline subtype, composed of cysts and
vesicles surrounded by dense connective tissue. Note the
hourglass-shaped cystic spaces, considered to imitate the transfor-
mation of the primary to the secondary yolk sac ( x 100).
performance status, 0 = 1, = 2, 2 = 3, 3 = 4, 4 = 5; residual
tumour size; nil or micro = 1, <2 cm = 2, >2 cm to
(5 cm = 3, >5 cm =4. In FIGO stage I cases alone, the
variables in the Cox model were as follows: FIGO stage I
subclasses, Ia = 1, lb = 1, Ic = 2; number of histological sub-
types, one = 3, two = 2, three or four = 1; chemotherapy,
cisplatin-based chemotherapies = 1, others = 2. All analyses
were performed with standard packages from the Statistical
Analysis System (SAS, Cary, NC, USA) (SAS Institute, 1983,
1985) by S. Tsugane (National Cancer Research Institute,
Tokyo, Japan).
Results
Clinicalfindings
The mean age at diagnosis for all patients was 20.05 years
(range 1-48 years) with a unimodal distribution. Seventeen
patients (20%) were stage I, four patients (11.4%) were stage
II, 12 patients (34.3%) were stage III and two patients
(5.7%) were stage IV. Preoperative levels ofalpha-fetoprotein
were measured in 27 patients, with a mean value of 18,952 ng
ml-' (range 20-206,000 ng ml-'). Nine patients (25.8%)
were Karnofsky's performance status (PS) 0, six patients
(17.1%) were PS 1, three patients (8.6%) were PS 2, one
patient (2.9%) was PS 3, one patient (2.9%) was PS 4 and in
15 patients (42.9) PS was unknown. All patients underwent
primary surgery. Eleven women (31.4%) were treated with
SO. Only one patient (2.9%) received BSO. Fifteen women
(42.9%) had BSO + TAH. The remaining eight patients
(22.9%) received either SO, BSO or BSO + TAH with para-
aortic or pelvic lymphadenectomy. Omentectomy was per-
formed in three patients (8.6%) and bowel diversion in 17
(48.6%). Biopsy was performed to determine the diagnosis in
one patient (2.8%). Thirty-three of 35 patients (94.3%)
received adjuvant chemotherapy. Eleven of 35 patients
(31.4%) were treated with VAC following the primary
surgery. Of these 11 patients, four survived for 680-1692
days and seven died between 254 and 1,248 days after
primary therapy. The mean and standard deviation of the
number of courses of VAC given to the two groups were
13.0 ± 6.98 in survivors and 15.3 ± 11.0 in non-survivors.
There was no statistically significant difference in the number
of courses of VAC (P>0.05, t-test). Thirteen of 35 patients
(37.1%) were treated with cisplatin-based chemotherapy
(PVB, 6; PAC, 3; PEP, 3; PAF, 1). Of the 13 patients, eight
survived for 146-3,304 days and five died between 170 and
1,096 days after primary therapy. The number of courses of
PVB given to the two groups was 3.6 ± 2.5 in survivors and
5.0 ± 1.2 in non-survivors. There was no statistically
significant difference in the number of courses of PVB
(P>0.05, t-test). All of the three patients who received FAM
or FAMT died 398-935 days after primary therapy. Other
chemotherapeutic regimens were utilised in six patients
(20.0%): carboquinone + 5-FU (1), CPM + MMC (1), MMC
(1), ActD + carboquine (1), bleomycin (1) and methotrexate
(1). Two patients received no adjuvant chemotherapy.
Prevalence ofhistological subtypes
The prevalence of endodermal sinus subtype, polyvesicular
vitelline subtype, glandular subtype and hepatoid subtype of
YST is shown in Table I. The distribution of histological
subtypes in all stages is also shown in Table I. The ES
subtype was found in almost all (91.4%) YSTs. The other
three subtypes, PV (Figure 2), G (Figure 3) and H (Figure 4),
occurred much less frequently, with the PV subtype being
least frequent. On the other hand in FIGO stage I cases, the
frequency of ES subtype decreased, whereas that of PV, G
and H subtypes increased.
In addition, the number of subtypes admixed in YSTs was
examined (Table I). Fourteen patients (40.0%) showed one
histological subtype, with the predominant subtype being
endodermal sinus (ES), which was found in 12 patients
(34.3%). The other two tumours (5.7%) were composed of
the glandular subtype (G) only. There were no cases of pure532 H. SASAKI et al.
Figure 4 Hepatoid subtype composed of solid aggregates of
masses of hepatocyte-like cells. Glands are also seen within the
solid areas ( x 100).
hepatoid (H) or polyvesicular vitelline (PV) subtype. Twelve
tumours (34.3%) showed an admixture of two subtypes:
ES+G (4); EP+PV (3), ES+H (3) or G+H (1). No
tumour was composed of another combination of two sub-
types. Six tumours (17.1%) showed a mixture of three sub-
types, ES + PV + H (4) or ES + G + H (2). Three tumours
(8.6%) showed an admixture of all four subtypes. The mean
numbers of tissue sections per tumour with three or four
subtypes (15.00 ± 12.52 and 11.33 ± 5.03 respectively) were
more than for those with one or two subtypes (5.57 ± 5.05
and 6.58 ± 3.45 respectively). However, they showed no
statistically significant differences (P>0.05, t-test) (Table I).
Univariate analysis ofprognostic variables relating to death
Correlation between survival and clinical, histological and
therapeutic parameters is shown in Table II. The significant
predictors were FIGO stage (P = 0.0002, Wilcoxon rank
test), residual tumour size (P = 0.004, Wilcoxon rank test)
and number of histological subtypes (P = 0.02, Wilcoxon
rank test). The mortality rate increases with residual tumour
size and number of histological subtypes. Patients with
advanced disease (stage III or IV) had extremely poor sur-
vival rates. The P-value for chemotherapy regimen was 0.10
(Wilcoxon rank test). Cisplatin-based chemotherapies and
VAC therapy were associated with better prognosis than
FAM or FAMT and others. The survival rate increased with
age, showing a sharp decrease below 10 years of age at the
time of first treatment. Alpha-fetoprotein was not a signifi-
cant factor (P = 0.5, Wilcoxon rank test). Performance status
was not a significant factor either (P = 0.02, Wilcoxon rank
test).
Multivariate analysis
The results of multivariate analysis of the above-mentioned
parameters based on mortality rate are summarised in Table
III. The most important predictor was FIGO stage (P =
0.005). FIGO stage was the only independent variable deter-
mining the prognosis of patients with pure yolk sac tumours
of the ovary with respect to mortality. The second predictor
was the chemotherapy regimen (P = 0.09). Cisplatin-based
chemotherapies were associated with a significantly better
prognosis than FAM, FAMT or other regimens (P<0.05).
The third factor was residual tumour size (P = 0.1). The
histological subtype was fourth, followed by age, and was
not significant as a prognostic factor (P = 0.6).
The results of multivariate analysis of mortality rates for
TableII Univariatepredictors ofsurvival(log-rank testandWilcoxon ranktestbySAS)
in pure yolk sac tumours of the ovary
Three-year
No. of survival rate Log-rank test Wilcoxon rank
patients (%) P-value test P-value
FIGO stage
I and II 21 70.00
III and IV 14 7.74 0.0001 0.0002
Residual tumour size
Micro or no tumour 23 58.00
>micro 12 16.67 0.0007 0.004
Age (years)
(20 15 28.85
>20 20 45.38 0.20 0.08
Performance status
0 9 51.85
> 1 11 26.67 0.2 0.2
Unknown 15
Alpha-fetoprotein (ng ml- 1)
<5,000 14 25.17
>5,000 13 48.84 0.5 0.6
Unknown 8
No. of histological subtypes
One 14 23.1
Two 12 19.1 0.007 0.02
Three or four 9 100.0
Chemotherapies
PVB, CAP, PEP, 13 43.83
PAF, VAC 11 51.95 0.2 0.1
Others (Nil 2) 11 18.18
Abbreviations: PVB, cisplatin, vinblastine and bleomycin; PAC, cisplatin, adriamycin
and cyclophosphamide; PEP, cisplatin, etoposide and pepleomycin; PAF, cisplatin,
adriamycin and 5-fluorouracil; VAC, vincristine, dactinomycin and cyclophosphamide;
FAM, 5-fluorouracil, cyclophosphamide and mitomycin; FAMT, FAM and toyomycin.
Others (Nil 2): other regimens including two patients did not receive chemotherapy.
SAS: Allcalculations wereperformed by StatisticalAnalysis System(SASInstitute, 1983,
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Table III Multivariate analysis (Cox regression model) ofprognostic
factors for survival in 35 patients with pure yolk sac tumours of the
ovary
Prognostic Regression Standard Chi-square
factors studied coefficient error value p-value
FIGO stage 1.6201 0.5803 7.80 0.0052
Age 0.1861 0.6392 0.08 0.7709
Residual tumour 0.9231 0.6076 2.31 0.1287
size
No. of histological -0.2319 0.4145 0.31 0.5763
subtypes
Chemotherapy 0.7302 0.4362 2.80 0.0941
regimen
All calculations were performed by Statistical Analysis System (SAS
Institute, 1983, 1985).
Table IV Multivariate analysis (Cox regression model) ofprognostic
factors for survival in 17 patients with FIGO stage I, pure yolk sac
tumours of the ovary
Prognostic Regression Standard Chi-square
factors studied coefficient error value p-value
Age 0.0409 0.0537 0.5805 0.4461
FIGO stage I 1.1338 1.3501 0.7052 0.4010
subclassification
No. of histological 2.1846 1.0185 4.6007 0.0319
subtypes
Chemotherapeutic 0.2003 0.7178 0.0778 0.7802
regimen
All calculations were performed by Statistical Analysis System (SAS
Institute, 1983, 1985).
FIGO stage I cases alone are summarised in Table IV. The
residual tumour size was ignored as a parameter for multi-
variate analysis, because all patients with stage I disease had
relatively curative resection of the tumour without residual
tumour or with only ascites containing tumour cells. There-
fore, multivariate analysis for stage I patients was performed
with FIGO stage I subclass, histological subtype, age and
chemotherapy as prognostic factors. The histological subtype
was a significant predictor in FIGO stage I patients (P =
0.03), and there were no other significant predictors (Table
IV). Therefore, the admixture of histological subtypes was an
important prognostic factor in FIGO stage I patients.
Patient characteristics related to histological subtypes in stage
Ipatients
Table V shows the clinical features of FIGO stage I patients
with pure yolk sac tumour with different histological sub-
types containing one, two and three or four components. All
patients with FIGO stage I disease had relatively curative
resection of the tumour with no residual tumour or with only
ascites containing tumour cells. Subclassification of FIGO
stage I tumours revealed that nine were stage Ia and eight
stage Ic. When the number of histological subtypes was
classified, FIGO stage I subclassifications of pure yolk sac
tumours containing one, two and three or four histological
subtypes showed no significant difference (P = 1.00, chi-
square test). The 17 patients in FIGO stage I were aged
11-48 years (mean ± s.d. 26.24 ± 10.25). There were no
patients below 10 years of age in FIGO stage I. However, the
mean age of patients with an admixture of two histological
subtypes was significantly higher than both those with one
and those with three or four histological subtypes (P<0.05,
t-test). Nine of 17 patients with FIGO stage I had undergone
unilateral salpingo-oophorectomy. Only one patient had bi-
lateral salpingo-oophorectomy. Three of 17 patients had
bilateral salpingo-oophorectomy and total hysterectomy.
Lymphadenectomy was performed in four of 17 patients.
There were no statistically significant differences in the sur-
gical procedures of the three groups with one, two and three
or four histological subtypes admixed (P = 0.06, chi-square
test). Sixteen of 17 patients with FIGO stage I disease had
received chemotherapy, with five patients receiving VAC, two
PVB, three PEP, one PAF, one CAP, one FAMT and three
other regimens. There were no significant differences between
the three groups with respective P-values of0.7, 0.1 and 0.06
(chi-square test). The number of histopathological slides
radiation therapy and recurrence at second-look operation as
patient background showed no significant differences between
the three groups with respective P values of 0.7, 0.1 and 0.06
(chi-square test). The number of histopathological slides
showed no statistically significant differences between the
three groups with different numbers of histological subtypes
(P>0.05, t-test).
Figure 5 shows the survival in the three FIGO stage I
groups with different numbers of histological subtypes using
the Kaplan-Meier method. Four-year survival rates of the
patient with one subtype and two subtypes were both 25%.
On the other hand, all patients with three or four subtypes
were alive with no evidence of disease 404-3056 days after
primary therapy. There were statistically significant differ-
ences in survival between the patients with three or four
subtypes and those with one or two subtypes (P<0.01,
log-rank test).
Discussion
Yolk sac tumour (YST) was previously called endodermal
sinus tumour because of its resemblance to the endodermal
sinus of the rat yolk sac (Teilum, 1959). The pathological
diagnosis of yolk sac tumour (YST) depends upon the recog-
nition of a number of different subtypes. The first concept
regarding the histopathological subtypes of endodermal sinus
tumour was based largely on the work ofTeilum (1959, 1965,
1968, 1976). Subsequently, Kurman and Norris (1976) classi-
fied ovarian YSTs into four basic subtypes: reticular (micro-
cystic), festoon (pseudopapillary or perivascular), polyvesicular
vitelline and solid (Duval, 1891). Most YSTs showed a com-
bination of two or more of the four major histological sub-
types. YSTs composed of a single histological subtype were
all of the reticular type. Either a predominant or focal
reticular subtype occurred in 98% of tumours; a solid sub-
type occurred in 86%, a festoon subtype in 54% and a
polyvesicular vitelline subtype occurred most rarely in 8% of
YSTs. Our criteria for ES subtype were based on Kurman's
reticular subtype and the presence of Schiller-Duval bodies.
In this study, ES subtype was predominant, occurring in
91.4% of tumours. This result is similar to the prevalence
obtained from Kurman's classification. Our criteria for poly-
vesicular vitellline subtype were also based on Kurman's. PV
subtype occurred in 28.6% of YSTs in this study. The differ-
ence from Kurman's result may be due to the race of the
study population.
In the present study, the definition of the hepatoid sub-
type, which was first described by Prat et al. (1982), was
based on Ulbright's criteria (Ulbright et al., 1986), i.e.
hepatoid areas characterised by nest and cords of polygonal,
acidophilic cells with prominent nucleoli and intense cyto-
plasmic staining for alpha-fetoprotein. Ulbright et al. (1986)
noted that this subtype occurred in 22% of YSTs. We found
a slightly higher prevalence of 40%.
Enteric differentiation occurred as well-defined glands with
a sharp, striated border and relatively bland nuclear features
(Ulbright et al., 1986). Salazar et al. (1974) described the
presence of Paneth cells, gastric-type parietal cells and un-
differentiated intestinal crypt cells in ultrastructural studies of
YSTs. Our criteria for glandular subtype were based on the
criteria of Ulbright et al. (1986) for enteric differentiation,
and consisted of the following features: the formation of
well-defined glands by cells with a visible striated border and
nuclei with more diffuse chromatin and smaller (or absent)
nucleoli than the nuclei of the surrounding YST cells. Kur-
man and Norris (1976) described similar glandular structures
in YSTs. The G subtype occurred in 31.4% of YSTs. This
value is nearly the same as the 34% prevalence reported for534 H. SASAKI et al.
Table V Background ofpatients with stage I pureyolk sac tumours containing one, two and three or four
histological subtypes
No. of patients
Age (years)
FIGO stage
Ia
lb
Ic
Surgery
Complete
Incomplete
Surgical procedure
SO
BSO
TAH + BSO
PA or PL lymph-
adenocetomy with SO
or BSO
Chemotherapy
Nil
Treated
VAC
FAMT
CAP
PVB
Others
No. of chemotherapy
courses (unknown 2)
Supporting chemotherapy
Nil
Treated
Unknown
Radiation therapy
Nil
Treated
AFP (ngml-')
Unknown
No. of histopathological
slides
One
subtype
5
22.8± 11.45a
(11,11,25,
31,36)
3
0
2
5
0
4
0
0
1 0
5
0
1 0
3
1,8,9
4
1
0
3
2
1,577+ 1,749
20, 1,240, 3,470
2
6.4± 3.21
2, 5,6,9, 10
Recurrence at second-look operation
Nil 2
Present 3
Two
subtypes
5
32.0± 11.79b
(19,23,31,
39,48)
2
0
3
5
0
0
1
2
2
0
5
2
0
0
2
1
1,7,10,16,25e,f
4
0
1
5
0
41,692±76,767h
108, 1,650, 13,400
14,800, 178,500
0
7.6+4.04k,'
3, 6, 7, 8, 14
3
2
Three orfour
subtypes
7
24.57+8.75c,d
(14,14,22,23,
30,34,35)
4
0
3
7
0
S
0
1
1
0
7
3
0
3
1
1
3,3,7.7,109
16,21
3
2
2
7
0
5,952± 3,365Uj
200, 4,500, 6,160
6,850, 8,000, 104
1
15.71 ± 11.21m
6, 11, 12, 12,
13, 16, 40
7
0
aMean±standarddeviation.b,e,bhkOnesubtype vstwosubtypes;C,f,i'iTwosubtypesvsthreeorfoursubtypes.
dgjmOne subtypes vs three or four subtypes. Abbreviations: SO, salpingo-oophorectomy; BSO, bilateral
salpingo-oophorectomy; TAH, transabdominal total hysterectomy; Pel, pelvic; Pan, para-aortic; LNX,
lymphadenectomy; Nil, no treatment; VAC, vincristine, dactinomycin, cyclophosphamide; FAMT,
5-fluorouracil, cyclophosphamide, mitomycin, toyomycin; PAC, cisplatin, adriamycin, cyclophosphamide;
PVB, cisplatin, vinblastine, bleomycin; *NS, not significant (P<0.05, t-test); **NS, not significant
compared with CDPP-based chemotherapy, VAC, FAM or FAMT and others.
Ulbright's enteric differentiation (Ulbright et al., 1986).
Recently, the International Society of Gynecological Patho-
logists proposed a new classification of YST of the ovary
(International Society of Gynecological Pathologists, 1990).
In the new classification, YST was subdivided into five
groups: endodermal sinus tumour, polyvesicular vitelline
variant, glandular variant, hepatoid variant and mixed type.
The classification of YSTs was based on ES, PV, G and H
subtypes. Hence, we classified YST according to the five
subtypes (SAS Institute, 1985). There is interest in the clinical
significance of the new classification of YST of the ovary.
First, a study of the correlation between histological subtypes
and prognosis was performed by Kurman and Norris (1976),
who divided YSTs into five main histological subtypes. How-
ever, there was no correlation of these subtypes with prog-
nosis. Nogales et al. (1978) reported that a pure polyvesicular
vitelline subtype was associated with a better outcome for
patients with testicular YST. However, there is currently no
information to suggest that glandular and hepatoid subtypes
are biologically different from other types of ovarian YST.
In the present study, multivariate analysis of all variables
demonstrated that chemotherapeutic regimen, residual
tumour size and FIGO stage are more important prognostic
factors than the number of histological subtypes. Other
investigators have reached similar conclusions (Kurman &
Norris, 1976; Bradof et al., 1982; Taylor et al., 1985; Carlson
et al., 1983; Davis et al., 1984). However, there have been
few reports about the prognostic significance of histological
Statistical
significance
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Figure 5 Survival related to the number of histological subtypes
in FIGO stage I patients with ovarian pure yolk sac tumours
calculated by the Kaplan-Meier methods. a, One subtype (five
patients); b, two subtypes (five patients); c, three or four subtypes
(seven patients). Survival times were calculated from the time of
primary therapy to death.
subtypes in FIGO stage I YST of the ovary (Julian et al.,
1980). Hence, in the present series, only stage I patients were
further analysed to evaluate the prognostic significance of the
various histological subtypes.
In patients with FIGO stage I disease, residual tumour
size, FIGO stage I subclassification, age and chemotherapy
were not important as prognostic factors. All patients with
FIGO stage I disease had relatively complete surgery without
residual tumour or with only ascites containing tumour cells.
Surgical procedures, especially SO or BSO and TAH + BSO,
had similar outcomes. Therefore, residual tumour size was
ignored as a prognostic factor. In the subclassification of
FIGO stage I, although stage Ic patients had worse prognosis
than stage Ia or lb patients, the survival difference between
stage Ia or lb and Ic was small. In addition, there was no
bias concerning stage Ic between the group with one histo-
logical subtype and those with an admixture, since the
disease stage in groups with one, two and three or four
subtypes showed no significant differences (P = 1.00). Multi-
variate analysis showed that the subclassification of FIGO
stage I had less significance than histological subtype. Ein-
horn, Gershenson and other investigators have reported that
cisplatin-based regimens (PVB and BEP) is more effective
than VAC in the treatment of ovarian germ cell tumours
(Einhorn & Donohue, 1977; Julian et al., 1980; Carlson et
al., 1983; Davis et al., 1984). However, our data showed that
chemotherapy regimen was not a significant predictor in
FIGO stage I patients. In FIGO stage I, VAC produced a
high proportion of cures, but in patients with metastatic
disease the sustained remission rates of cisplatin-based
chemotherapies are better than that of VAC (Pinkerton et
al., 1986; Williams et al., 1989; Gershenson et al., 1990).
Therefore, our results of multivariate analysis in FIGO stage
I patients are not consistent with other reports concerning
chemotherapy for ovarian YST. In addition, there were no
significant differences between groups with an admixture of
histological subtypes and that with one subtype with respect
to the number of patients treated with cisplatin-based chemo-
therapies, although patients with three or four subtypes had
a better outcome than patients in other groups.
Next, age was considered as a possible prognostic factor.
Some investigators have reported that there are no significant
differences in prognosis between those younger and older
than 20 years of age (Kurman & Norris, 1976; Kawai et al.,
1991). In the present study, multivariate analysis showed the
same result as other reports. In addition, patients less than 10
years of age are known to have a worse prognosis, and in
our series no FIGO stage I patient was less than 10 years
old.
There were no statistically significant differences in the
factors mentioned above among the three groups with differ-
ent numbers of histological subtypes. However, there was a
significant difference in alpha-fetoprotein between the stage I
patients with two subtypes and those with three or four
subtypes. However, both univariate and multivariate analysis
showed no prognostic significance in relation to alpha-feto-
protein in this study. There are previous reports indicating
that preoperative alpha-fetoprotein levels do not correlate
with prognosis (Kawai et al., 1991). Therefore, it can be
considered that histological subtype is superior to other fac-
tors as a predictor in FIGO stage I YST of the ovary.
When we focused on the number of histopathological
slides, there were variations in the numbers of slides exa-
mined for each histological subtype. The mean number of
slides studied for tumours containing three or four subtypes
was greater than that for tumours with one or two subtypes.
There was a wide variation in the number of slides reviewed
per patient. However, when statistical analysis was per-
formed, there were no significant differences between
tumours with one or two subtypes and those with three or
four subtypes. However, when the group with three or four
subtypes was separated for comparison with other groups,
comparison of the group with one subtype and that with
three subtypes showed a significant difference. Even though
there were no significant differences in comparing the
numbers of slides examined in the groups with three or four
subtypes with other groups, it was thought that the number
of subtypes might increase in some cases after histopatho-
logical examination of a large number of slides, especially in
the tumours containing only one subtype.
Generally, it is agreed that well-differentiated germ cell
tumours have better prognosis than undifferentiated ones. In
comparing embryonic structures with neoplastic subtypes,
YSTs containing three or four distinct subtypes may be
better differentiated tumours that pure endodermal sinus
tumours. If the concept were reasonable, it would be that
patients with tumours containing three or four subtypes have
a better prognosis than those with tumours containing one or
two subtypes. Therefore, it could be clinically important to
investigate the prognostic significance of histological subtype
in stage I YST. The present study was a retrospective inves-
tigation, and may have a bias in the numbers of histopatho-
logical slides examined. We consider that a prospective study
with identical pathological examinations is necessary to con-
firm the correlation between histological subtype and the
clinical outcome in stage I pure yolk sac tumour of the
ovary.
Although stage I pure yolk sac tumour generally has a
good prognosis, the present study suggests that the different
subtypes may have prognostic significance. In particular,
endodermal sinus subtype alone is associated with a poor
prognosis, which may have therapeutic implications.
The authors thank Hisayoshi Nakajima, Michiaki Yakushiji, Haruo
Nishimura, Shigeaki Iwanaga, Shoji Jimi, Hisao Nakano, Naoki
Tsukamoto, Akisuke Moriwaki, Masamichi Hiura, Michi Chiba,
Yutaka Tomoda, Takeo Kanou, Mitihata Kawai, Nobuo Nakajima,
Takahiko Sonodo, Shin Fukutomi, Katsuhiko Hasumi, Hideo
Teshima, Masahiko Nishijima, Hiroyuki Kuramoto, Toshiko Jou-
boub, Satoshi Yajima, Shinji Satou, Tsuneo Namiki, Ijirou
Morizuka, Kenichi Tanaka, Kouji Kanazawa, Syouji Kodama,
Masatoshi Hashimoto, Ryuuichi Kudoh and Osamu Hayakawa for
the supply of patient samples in this study. The authors thank Dr
T.A. Tavassoli (Armed Forces Institue of Pathology, Washington
DC 20306-6000) and Dr W. Gray (University of Otago, New Zea-
land) for help with preparation of the manuscript.536 H. SASAKI et al.
References
BRADOF, J.E., HAKES, T.B., OCHOA, M. & GOLBEY, R. (1982). Germ
cell malignancies of the ovary. Treatment with vinblastine,
actinomycin D, bleomycin and cisplatin containing chemotherapy
combinations. Cancer, 50, 1070-1075.
CARLSON, R.W., SIKIC, B.I., TURBOW, M.M. & BALLON, S.C. (1983).
Combination cisplatin, vinblastine and bleomycin chemotherapy
(PVB) for malignant germ-cell tumors of the ovary. J. Clin.
Oncol., 1, 645-651.
COX, D.R. (1972). Regression models and life tables. J. R Stat. Soc.,
34, 187.
DAVIS, T.E., LOPRINZI, C.L. & BUCHLER, D.A. (1984). Combination
chemotherapy with cisplatin, vinblastine and bleomycin for endo-
dermal sinus tumor of the ovary. Gynecol. Oncol., 19, 46-52.
DUVAL, M. (1891). Le placenta de rongeurs. J. Anat. Physiol., 27,
515-612.
EINHORN, L.H. & DONOHUE, J. (1977). Cisdiamine dichloro-
platinum, vinblastine, and bleomycin combination chemotherapy
in disseminated testicular cancer. Ann. Intern. Med., 87, 293-298.
GERSHENSON, D.M., COPELAND, L.J., KAVANAGH, J.J., CANGIR,
A., DEL JUNCO, G., SAUL, P.B., STRINGER, C.A., FREEDMAN,
R.S., EDWARDS, C.L. & WHARTON, J.T. (1985). Treatment of
malignant nondysgerminomatous germ cell tumors of the ovary
with vincristine, dactinomycin and cyclophosphamide. Cancer,
56, 2756-2761.
GERSHENSON, D.M., MORRIS, M., CANGIR, A., KAVANAGH, J.J.,
STRINGER, C.A. & EDWARDS, C.L. (1990). Treatment of malig-
nant germ cell tumors of the ovary with bleomycin, etoposide
and cisplatin (BEP). J. Clin. Oncol., 8, 715-720.
HUNTINGTON JR, R.W. & BULLOCK, W.K. (1970). Yolk sac tumors
of the ovary. Cancer, 25, 1357-1367.
HUNTINGTON JR, R.W., MORGENSTERN, N.L., SARGENT, J.A.,
GIEM, R.N., RICHARDS, A. & HANFORD, K. (1963). Germinal
tumors exhibiting the endodermal sinus pattern of Teilum in
young children. Cancer, 16, 34-47.
INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTET-
RICS (1988). Annual Report on the Results of Treatment in
Gynecological Cancer, Vol. 20. Pettersson, F. (ed.), p. 111, Panor-
ama Press: Stockholm.
INTERNATIONAL SOCIETY OF GYNECOLOGIC PATHOLOGY (1990).
The new classification of ovarian tumours. In Proceedings of
International Academy of Pathology, in Buenos Aires.
JIMERSON, G.K. & WOODRUFF, J.D. (1977). Ovarian extraembryonal
teratoma. 1. Endodermal sinus tumor. Am. J Obstet. Gynecol.,
127, 73-79.
JULIAN, C.G., BARRETT, J.M., RICHARDSON, R.L. & GRECO, F.A.
(1980). Bleomycin, vinblastine, and cis-platinum in the treatment
of advanced endodermal sinus tumor. Obstet. Gynecol., 56,
396-401.
KAPLAN, E. & MEIER, P. (1958). Non-parametric estimations from
incomplete observations. J. Am. Stat. Assoc., 53, 457-482.
KAWAI, M., KANO, T., FURUHASHI, Y., MIZUNO, K., NAKASHIMA,
N., HATTORI, S., KAZETO, S., IIDA, S., OHTA, M., ARII, Y. &
TOMODA, Y. (1991). Prognostic factors in yolk sac tumors of the
ovary. A clinicopathologic analysis of 29 cases. Cancer, 67,
184-192.
KURMAN, R.J. & NORRIS, H.J. (1976). Endodermal sinus tumor of
the ovary: a clinical and pathologic analysis of 71 cases. Cancer,
38, 2404-2419.
NEUBECCKER, R.D. & BREEN, J.L. (1962). Embryonal carcinoma of
the ovary. Cancer, 15, 546-556.
NOGALES, F.F., MANTILLA, A., NOGALES-ORTIZ, F. & GALERA-
DAVIDSON, H.L. (1978). Yolk sac tumors with pure and mixed
polyvitelline subtypes. Hum. Pathol., 9, 553-566.
PINKERTON, C.R., PRITCHARD, J. & SPITZ, L. (1986). High complete
response rate in children with advanced germ cell tumors using
cisplatin-containing combination chemotherapy. J. Clin. Oncol.,
4, 194-199.
PRAT, J., BHAN, A.K., DICKERSIN, G.R., ROBBOY, S.J. & SCULLY,
R.E. (1982). Hepatoid yolk sac tumor of the ovary (endodermal
sinus tumor with hepatoid differentiation): a light microscopic,
ultrastructural and immunohistochemical study of seven cases.
Cancer, 50, 2355-2368.
SALAZAR, H., KANBOUR, A., TOBON, H. & GONZALEZ-ANGALO, A.
(1974). Endoderm cell derivatives in embryonal carcinoma of
ovary. An electron microscopic study of two cases (abstract). Am.
J. Pathol., 74, 108a.
SAS INSTITUTE (1983). SUGI Supplemental Library User's Guide,
pp. 267-294. SAS Institute: Cary, NC.
SAS INSTITUTE (1985). SAS User's Guide: Statistics, version 5,
pp. 529-557. SAS Institute: Cary, NC.
SMALES, E. & PECKMAN, M.J. (1987). Chemotherapy of germ-cell
ovarian tumours: first-line treatment with etoposide, bleomycin
and cisplatin or carboplatin. Eur. J. Cancer Clin. Oncol., 23,
469-474.
TALERMAN, A., HAIJE, W.G. & BAGGERMAN, L. (1978). Serum
alpha-fetoprotein in diagnosis and management of endodermal
sinus (yolk sac tumor) and mixed germ cell tumor of the ovary.
Cancer, 41, 272-278.
TAYLOR, M.H., DEPETRILLO, A.D. & TURNER, A.R. (1985). Vinblas-
tine, bleomycin and cisplatin in malignant germ cell tumors ofthe
ovary. Cancer, 56, 1341-1349.
TEILUM, G. (1959). Endodermal sinus tumors of the ovary and testis.
Comparative morphogenesis of the so-called mesonephroma
ovarii (Schiller) and extraembrynic (yolk sac-allantoic) structures
of the rat's placenta. Cancer, 12, 1092-1105.
TEILUM, G. (1965). Classification of endodermal sinus tumour
(mesoblastoma vitellinum) and so-called embryonal carcinoma of
the ovary. Acta Pathol. Microbiol. Scand., 64, 407-429.
TEILUM, G. (1968). Tumours of germinal origin. In Ovarian
Cancer,UICC Monograph Series, Vol. 11, Gentil, F. & Jun-
queira, A.C. (eds) pp. 58-73. Springer: Berlin.
TEILUM, G. (1976). Special Tumors of the Ovary and Testis. Com-
parative Histology and Identification, 2nd edn. Munksgaard:
Copenhagen.
ULBRIGHT, T.M., ROTH, L.M. & BRODHECKER, C.A. (1986). Yolk
sac differentiation in germ cell tumors. A morphologic study of
50 cases with emphasis on hepatic, enteric and parietal yolk sac
features. Am. J. Surg. Pathol., 10, 151-164.
WILLIAMS, S.D., BLESSING, J., SLAYTOR, R., HOMESLEY, H. &
PHOTOPOLUS, G. (1989). Ovarian germ cell tumors: adjuvant
trials of the Gynecologic Oncology Group (abstract). Proc. Am.
Soc. Clin. Oncol., 8, 150.